Clinical Trials Browser

INDUSTRY × pemigatinib × Clear all

NCT05267106 2025-12-30

FIGHT-209

Phase 2 Terminated

83 enrolled 18 charts

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT04463771 2025-12-10

POD1UM-204

Phase 2 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Phase 2 Completed

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase 2 Terminated

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03656536 2025-08-24

FIGHT-302

Phase 3 Terminated

Gastrointestinal

Cholangiocarcinoma

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 1 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Phase 2 Completed

8 enrolled 13 charts

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Phase 2 Terminated

10 enrolled 9 charts

Advanced Malignancies

NCT04256980 2024-05-30

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04003623 2022-05-10

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Phase 2 Terminated

1 enrolled 2 charts

Neoplasm Metastasis

NCT03906357 2022-04-19

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

No longer available

NCT04258527 2021-07-23

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT03235570 2020-05-29

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Phase 1 Completed

Acrocephalosyndactylia, Neoplasms